Aspirate from human stented native coronary arteries vs. saphenous vein grafts: more endothelin but less particulate debris.
暂无分享,去创建一个
[1] Fred S Apple,et al. Third universal definition of myocardial infarction , 2012 .
[2] S. Möhlenkamp,et al. Saphenous vein aorto-coronary graft atherosclerosis in patients with chronic kidney disease: more plaque calcification and necrosis, but less vasoconstrictor potential , 2012, Basic Research in Cardiology.
[3] R. Erbel,et al. Lessons from human coronary aspirate. , 2012, Journal of molecular and cellular cardiology.
[4] G. Levine,et al. 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. , 2011, Journal of the American College of Cardiology.
[5] S. Möhlenkamp,et al. Acute vasomotor paralysis and potential downstream effects of paclitaxel from stents implanted for saphenous vein aorto-coronary bypass stenosis , 2011, Basic Research in Cardiology.
[6] GerdHeusch,et al. Vasoconstrictor Potential of Coronary Aspirate From Patients Undergoing Stenting of Saphenous Vein Aortocoronary Bypass Grafts and Its Pharmacological Attenuation , 2011 .
[7] G. Heusch,et al. TNFalpha in atherosclerosis, myocardial ischemia/reperfusion and heart failure. , 2010, Pharmacology & therapeutics.
[8] S. Frisbee,et al. Aspirin resistance with genetic dyslipidemia: contribution of vascular thromboxane generation. , 2010, Physiological genomics.
[9] O. Muller,et al. Relation of endothelial function to residual platelet reactivity after clopidogrel in patients with stable angina pectoris undergoing percutaneous coronary intervention. , 2010, The American journal of cardiology.
[10] R. Erbel,et al. Coronary microembolization: from bedside to bench and back to bedside. , 2009, Circulation.
[11] W. J. van der Giessen,et al. Functional and Structural Adaptations of Coronary Microvessels Distal to a Chronic Coronary Artery Stenosis , 2008, Circulation research.
[12] K. Werdan,et al. Invited review: Vascular cells contribute to atherosclerosis by cytokine- and innate-immunity-related inflammatory mechanisms , 2008, Innate immunity.
[13] R. Virmani,et al. Long-term histological and immunohistochemical findings in human venous aorto-coronary bypass grafts. , 2008, Clinical science.
[14] J. Ormiston,et al. Distal embolization during native vessel and vein graft coronary intervention with a vascular protection device: predictors of high-risk lesions. , 2007, Journal of interventional cardiology.
[15] A. Feldman,et al. TNF-&agr; Contributes to Endothelial Dysfunction by Upregulating Arginase in Ischemia/Reperfusion Injury , 2007 .
[16] G. Maurer,et al. Active endothelin is an important vasoconstrictor in acute coronary thrombi , 2007, Thrombosis and Haemostasis.
[17] A. Feldman,et al. TNF-alpha contributes to endothelial dysfunction by upregulating arginase in ischemia/reperfusion injury. , 2007, Arteriosclerosis, thrombosis, and vascular biology.
[18] E. Romagnoli,et al. Endothelin-1 and acute myocardial infarction: a no-reflow mediator after successful percutaneous myocardial revascularization. , 2006, European heart journal.
[19] R. Erbel,et al. Intense vasoconstriction in response to aspirate from stented saphenous vein aortocoronary bypass grafts. , 2006, Journal of the American College of Cardiology.
[20] A. Jacobs,et al. Aspirin resistance and atherothrombotic disease. , 2005, Journal of the American College of Cardiology.
[21] N. Weissman,et al. Incidence and clinical correlates of ruptured plaques in saphenous vein grafts: an intravascular ultrasound study. , 2005, Journal of the American College of Cardiology.
[22] W. Chilian,et al. Cardiac myocytes control release of endothelin-1 in coronary vasculature. , 2005, American journal of physiology. Heart and circulatory physiology.
[23] 白井 伸幸. Expression of endothelin-converting enzyme, endothelin-1 and endothelin receptors at the site of percutaneous coronary intervention in humans , 2005 .
[24] K. Kent,et al. Effect of direct stenting on clinical outcome in patients treated with percutaneous coronary intervention on saphenous vein graft. , 2003, American heart journal.
[25] G. Stone,et al. Randomized Comparison of Distal Protection With a Filter-Based Catheter and a Balloon Occlusion and Aspiration System During Percutaneous Intervention of Diseased Saphenous Vein Aorto-Coronary Bypass Grafts , 2003, Circulation.
[26] G. Maurer,et al. Coronary no-reflow is caused by shedding of active tissue factor from dissected atherosclerotic plaque. , 2002, Blood.
[27] M. Leon,et al. Randomized Trial of a Distal Embolic Protection Device During Percutaneous Intervention of Saphenous Vein Aorto-Coronary Bypass Grafts , 2002, Circulation.
[28] A. Yeung,et al. Prevention of Distal Embolization During Coronary Angioplasty in Saphenous Vein Grafts and Native Vessels Using Porous Filter Protection , 2001, Circulation.
[29] F. Cipollone,et al. Overexpression of Functionally Coupled Cyclooxygenase-2 and Prostaglandin E Synthase in Symptomatic Atherosclerotic Plaques as a Basis of Prostaglandin E2-Dependent Plaque Instability , 2001, Circulation.
[30] C. Tracy,et al. American College of Cardiology Clinical Expert Consensus Document on Standards for Acquisition, Measurement and Reporting of Intravascular Ultrasound Studies (IVUS). A report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents. , 2001, Journal of the American College of Cardiology.
[31] T. Lüscher,et al. Endothelins and Endothelin Receptor Antagonists: Therapeutic Considerations for a Novel Class of Cardiovascular Drugs , 2000, Circulation.
[32] G. Caughey,et al. Differential Regulation of Prostaglandin E2 and Thromboxane A2 Production in Human Monocytes: Implications for the Use of Cyclooxygenase Inhibitors1 , 2000, The Journal of Immunology.
[33] F. Schaefer,et al. ANG II- and TxA2-induced mesenteric vasoconstriction in rats is mediated by separate cell signaling pathways. , 1999, American journal of physiology. Heart and circulatory physiology.
[34] T. Branchek,et al. Characterisation of 5-HT receptors in human coronary arteries by molecular and pharmacological techniques. , 1999, European journal of pharmacology.
[35] C. White,et al. Morphologic comparison of atherosclerotic lesions in native coronary arteries and saphenous vein graphs with intracoronary angioscopy in patients with unstable angina. , 1998, American heart journal.
[36] E J Topol,et al. Aortocoronary saphenous vein graft disease: pathogenesis, predisposition, and prevention. , 1998, Circulation.
[37] R. Erbel,et al. Comparison of myocardial perfusion reserve before and after coronary balloon predilatation and after stent implantation in patients with postangioplasty restenosis. , 1996, Circulation.
[38] J. Maclouf,et al. Cyclooxygenases-1 and −2 of Endothelial Cells Utilize Exogenous or Endogenous Arachidonic Acid for Transcellular Production of Thromboxane (*) , 1996, The Journal of Biological Chemistry.
[39] Y. Nishimura,et al. ENHANCED CONTRACTILE RESPONSES MEDIATED BY DIFFERENT 5‐HT RECEPTOR SUBTYPES IN BASILAR ARTERIES, SUPERIOR MESENTERIC ARTERIES AND THORACIC AORTAS FROM STROKE‐PRONE SPONTANEOUSLY HYPERTENSIVE RATS , 1995, Clinical and experimental pharmacology & physiology. Supplement.
[40] A. Zeiher,et al. Tissue endothelin-1 immunoreactivity in the active coronary atherosclerotic plaque. A clue to the mechanism of increased vasoreactivity of the culprit lesion in unstable angina. , 1995, Circulation.
[41] F. Zijlstra,et al. Low‐Dose Aspirin Inhibits Platelet‐Induced Contraction of the Human Isolated Coronary Artery: A Role for Additional 5 ‐Hydroxytryptamine Receptor Antagonism Against Coronary Vasospasm? , 1994, Circulation.
[42] M. Yacoub,et al. Interaction Between Thromboxane A2 and 5‐Hydroxytryptamine Receptor Subtpes in Human Coronary Arteries , 1993, Circulation.
[43] W. Ganz,et al. The thrombolysis in myocardial infarction (TIMI) trial. , 1985, The New England journal of medicine.
[44] H. S. Mueller,et al. The Thrombolysis in Myocardial Infarction (TIMI) trial. Phase I findings. , 1985, The New England journal of medicine.